Treatment of cancer with a parg inhibitor

A method of treating a cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising (R)-1-methyl-4-((1-methyl-1H-pyrazol-4-yl)methyl-d2)-N-(1-methylcyclopropyl)-5-oxo-1,2,4,5-tetrahydroimidazo[1,2-a]quinazoline-7-sulfonamide, or pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

The method of any one of the preceding claims, wherein the cancer is metastatic.

The method of any one of the preceding claims, wherein the method is adjuvant therapy following surgical resection.

The method of any one of the preceding claims, wherein the method is neo-adjuvant therapy.

A method of treating a cancer in a patient in need thereof, comprising administering to the patient:

• (a) a composition comprising (R)-1-methyl-4-((1-methyl-1H-pyrazol-4-yl)methyl-d2)-N-(1-methylcyclopropyl)-5-oxo-1,2,4,5-tetrahydroimidazo[1,2-a]quinazoline-7-sulfonamide, or pharmaceutically acceptable salt or solvate thereof;
• and
• (b) at least one oncology therapeutic selected from a DNA damaging agent, a platinum-based chemotherapy, a DNA damage response inhibitor, cell cycle checkpoint inhibitor, a nucleotide metabolism inhibitor, a nucleotide synthesis inhibitor, an endocrine therapy, a hormonal therapy, a SERM therapy, a SERD therapy, an androgen deprivation therapy, a novel hormone therapy, a taxane, a topoisomerase inhibitor, an anti-VEGF therapeutic, an immune checkpoint inhibitor, a kinase inhibitor, a K-RAS inhibitor, a phosphatidylinositol 3-kinases (PI3K) inhibitor, an antibody drug conjugate (ADC), or a radiopharmaceutical.

The method of any one of the preceding claims, wherein the (R)-1-methyl-4-((1-methyl-1H-pyrazol-4-yl)methyl-d2)-N-(1-methylcyclopropyl)-5-oxo-1,2,4,5-tetrahydroimidazo[1,2-a]quinazoline-7-sulfonamide, or pharmaceutically acceptable salt or solvate thereof, is administered orally.

The method of any one of the preceding claims, wherein the oral administration occurs once per day, twice per day, three times per day, every other day, or one to five days per week.

The method of any one of the preceding claims, wherein the method further comprises administration to the patient of a NAD+ precursor.